Genetics of Parkinson Disease: Paradigm Shifts and Future Prospects
Key Insights
Mutations in LRRK2 (search) (PARK8) cause autosomal-dominant late-onset Parkinson disease (search) with pleomorphic pathology, with the Gly2019Ser variant being the most frequent mutation identified to date.
α-Synuclein (search) locus triplication demonstrates that simple overexpression of wild-type protein is sufficient to cause disease, linking Parkinson disease (search) and dementia with Lewy bodies (search).
Mutations in PINK1 (search), Parkin (search), and DJ-1 (search) highlight the role of mitochondrial dysfunction and the ubiquitin-proteasome pathway in early-onset recessive parkinsonism.
The genetic architecture of Parkinson disease (search) has undergone a dramatic transformation over the past decade, shifting the paradigm from a purely environmental disorder to one with well-defined hereditary components. A comprehensive review published in Nature Reviews Genetics synthesizes the landmark discoveries that have reshaped understanding of the molecular pathogenesis of this common neurodegenerative condition.
The α-Synuclein (search) Story: From Gene to Pathology
The identification of the first Parkinson disease (search)-causing mutation in the α-synuclein (search) gene (SNCA) by Polymeropoulos and colleagues in 1997 marked a turning point in the field. The discovery of the Ala53Thr mutation in families with autosomal-dominant Parkinson disease provided the first direct genetic evidence for a causal link. Subsequent work by Singleton et al. in 2003 revealed that α-synuclein locus triplication causes Parkinson disease, demonstrating that simple overexpression of the wild-type protein is sufficient to trigger disease. This finding also suggested that Parkinson disease and dementia with Lewy bodies (search) share the same underlying etiology.
Further mutations were identified, including the Ala30Pro mutation described by Kruger et al. and the E46K mutation reported by Zarranz et al., which causes both Parkinson disease (search) and Lewy body dementia. The clinical heterogeneity of α-synuclein (search) gene duplication in autosomal-dominant familial Parkinson disease was later characterized by Nishioka et al., while Farrer et al. compared kindreds with parkinsonism and α-synuclein genomic multiplications, revealing a spectrum of clinical presentations.
Functional studies have provided critical mechanistic insights. Chen and Feany demonstrated in a Drosophila model that α-synuclein (search) phosphorylation controls neurotoxicity and inclusion formation, suggesting that α-synuclein inclusions and Lewy bodies might be protective rather than pathogenic. Lashuel et al. showed that α-synuclein, particularly the Parkinson disease (search)-associated mutants, forms pore-like annular and tubular protofibrils, pointing to potential toxic gain-of-function mechanisms.
LRRK2 (search): A Common Cause of Late-Onset Parkinson Disease (search)
The discovery of mutations in LRRK2 (search) (leucine-rich repeat kinase 2) as a cause of autosomal-dominant parkinsonism, reported simultaneously by Zimprich et al. and Paisan-Ruiz et al. in 2004, represented another major breakthrough. The PARK8 locus had been mapped to chromosome 12 by Funayama et al. in 2002, and the identification of the causative gene opened new avenues for understanding late-onset disease.
Kachergus et al. demonstrated that a common founder was responsible for the most frequent Parkinson disease (search)-causing mutation identified to date: LRRK2 (search) Gly2019Ser. Their work also provided age-associated penetrance estimates, critical for genetic counseling. The Gly2019Ser mutation has been found across diverse populations, including Ashkenazi Jews as reported by Ozelius et al., and North African Arabs as shown by Lesage and colleagues.
The clinical features of LRRK2 (search)-associated Parkinson disease (search) were detailed by Aasly et al. in a Norwegian cohort, while Tomiyama et al. conducted a clinicogenetic study of LRRK2 exon 41 mutations across 18 countries. Critically, West et al. and Gloeckner et al. demonstrated that LRRK2 substitutions augment kinase activity, indicating the therapeutic possibility of kinase inhibition as a neuroprotective strategy in Parkinson disease.
Recessive Genes and the Ubiquitin-Proteasome Pathway
The discovery of Parkin (search) mutations by Kitada et al. in 1998 as a cause of autosomal recessive juvenile parkinsonism was the first gene implicated in early-onset disease. Shimura et al. subsequently demonstrated that the Parkin gene product functions as a ubiquitin-protein ligase, highlighting the role of the ubiquitin-proteasome pathway in pure nigral neuronal degeneration.
Additional recessive genes followed: Bonifati et al. identified mutations in DJ-1 (search) associated with autosomal recessive early-onset parkinsonism in 2003, while Valente et al. reported that mutations in PINK1 (search) cause hereditary early-onset Parkinson disease (search) in 2004. PINK1 mutations were also found to be associated with sporadic early-onset parkinsonism, expanding the relevance of this gene beyond familial cases.
Functional studies have revealed that wild-type PINK1 (search) prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease (search)-related mutations, as shown by Petit et al. Beilina et al. demonstrated that PINK1 mutations have differential effects on protein stability. For DJ-1 (search), Zhang et al. reported mitochondrial localization, while Goldberg et al. showed that inactivation of DJ-1 causes nigrostriatal dopaminergic deficits and hypokinesia in mice.
Genetic Susceptibility and Risk Factors
Beyond monogenic forms, genetic risk factors for sporadic Parkinson disease (search) have been identified. Maraganore et al. conducted a high-resolution whole genome association study, while Pals et al. demonstrated that the α-synuclein (search) promoter confers susceptibility to Parkinson disease. Mueller et al. found that multiple regions of α-synuclein are associated with disease risk. The MAPT H1 haplotype has also been implicated through linkage disequilibrium and association studies by Skipper et al.
Therapeutic Implications
The genetic insights have begun to translate into therapeutic strategies. Masliah et al. demonstrated the power of genetic discoveries in nominating targets for translational advances, showing effects of α-synuclein (search) immunization in a mouse model of Parkinson disease (search). The finding that LRRK2 (search) mutations enhance kinase activity has made LRRK2 kinase inhibition an attractive neuroprotective approach.
The review emphasizes that Parkinson disease (search) is not a single entity but a syndrome with multiple genetic and environmental contributors. As Fahn described, the clinical syndrome of Parkinson disease encompasses heterogeneous pathologies, and genetic discoveries are increasingly revealing the molecular underpinnings of this complexity. The nosology of Parkinson disease, as discussed by Forman et al., continues to evolve as genetic and pathological findings challenge traditional diagnostic categories.